Table 2.
Relation between some clinical or tumor characteristics and tumor PET-derived image parameters in 143 patients with ER+/HER2- breast cancer
| Age | Tumora | Lymph nodesa | Histology | Grade | PR expression | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ≤40 | >40 | ≤50 | >50 | T2 | T3 | N0 | N+ | IDC | ILC | 1–2 | 3 | Neg | Pos | ||
| No. patients | 27 | 116 | 74 | 69 | 53 | 56 | 58 | 85 | 129 | 7 | 98 | 42 | 55 | 88 | |
| SUVmax | med | 5.4 | 6.8 | 6.5 | 6.6 | 5.2 | 5.9 | 6.1 | 6.6 | 6.8 | 4.8 | 5.4 | 7.9 | 7.2 | 5.7 |
| P | 0.31 | 0.63 | 0.56 | 0.79 | 0.43 | <0.01 | 0.06 | ||||||||
| SUVmean | med | 3.1 | 3.6 | 3.4 | 3.6 | 2.9 | 3.3 | 3.5 | 3.5 | 3.6 | 3.0 | 3.1 | 4.2 | 4.0 | 3.2 |
| P | 0.36 | 0.67 | 0.59 | 0.77 | 0.31 | <0.01 | 0.06 | ||||||||
| SUVpeak | med | 4.3 | 5.3 | 5.1 | 5.1 | 4.1 | 4.9 | 4.9 | 5.1 | 5.2 | 4.4 | 4.4 | 6.4 | 5.7 | 4.5 |
| P | 0.32 | 0.60 | 0.44 | 0.81 | 0.63 | <0.01 | 0.05b | ||||||||
| MATV | med | 10.1 | 11.2 | 11.0 | 9.6 | 6.7 | 10.8 | 9.2 | 11.3 | 10.1 | 32.5 | 10.9 | 10.4 | 13.9 | 9.1 |
| P | 0.33 | 0.86 | <0.01 | 0.24 | 0.02b | 0.83 | 0.03b | ||||||||
| TLG | med | 27.2 | 39.0 | 33.5 | 35.2 | 20.1 | 33.5 | 32.7 | 40.5 | 32.8 | 74.6 | 32.1 | 44.8 | 46.3 | 28.2 |
| P | 0.22 | 0.86 | <0.01 | 0.41 | 0.16 | 0.05b | 0.01b | ||||||||
| H | med | 0.12 | 0.12 | 0.12 | 0.12 | 0.11 | 0.12 | 0.12 | 0.12 | 0.12 | 0.14 | 0.12 | 0.12 | 0.13 | 0.12 |
| P | 0.81 | 0.87 | 0.02 | 0.10 | 0.09 | 0.73 | 0.12 | ||||||||
| E | med | 3.5 | 3.8 | 3.7 | 3.6 | 3.2 | 3.7 | 3.5 | 3.8 | 3.6 | 4.8 | 3.7 | 3.7 | 4.0 | 3.5 |
| P | 0.18 | 0.97 | <0.01 | 0.25 | 0.02b | 0.70 | 0.02b | ||||||||
P value for comparison of median values with the Wilcoxon rank sum test. Bold numerals correspond to P values keeping statistically significant after multiple corrections from Benjamini-Hochberg
PET positron emission tomography, ER+/HER2- estrogen receptor-positive/human epidermal growth factor receptor 2-negative, PR progesterone receptor, IDC invasive ductal carcinoma, ILC invasive lobular carcinoma, SUV standardized uptake value, MATV metabolically active tumor volume, TLG total lesion glycolysis, H homogeneity, E entropy
aClinical classification according to the seventh edition of the AJCC Cancer Staging Manual
bNot significant after correction for multiple testing